IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Juno Pharmaceuticals Pty Ltd v Janssen Pharmaceutica NV [2024] APO 48
Patent:2008340101
Title:Dosing regimen associated with long acting injectable paliperidone esters
Patentee:Janssen Pharmaceutica NV
Opponent:Juno Pharmaceuticals Pty Ltd
Delegate:Dr S. J. Smith
Decision Date: 4 December 2024
Hearing Date: 14 August 2024, by videoconference
Catchwords: PATENTS – section 104 – opposition to amendments – allowability under section 102 – sections 102(1), 102(2)(a), 102(2)(b) – what arises as a result of the amendment – amendments allowed – costs awarded against the opponent
Representation: Counsel for the patentee: Cynthia Cochrane SC
Patent attorney for the patentee: Katrina Crooks of Spruson & Ferguson Lawyers
Counsel for the opponent: Marcus Fleming
Patent attorney for the opponent: Paul Jones, Sarah Couper, Rosemary Manhire-Heath and Ellen Reid of Jones Tulloch
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent:2008340101
Title:Dosing regimen associated with long acting injectable paliperidone esters
Patentee:Janssen Pharmaceutica NV
Date of Decision: 4 December 2024
DECISION
The opposition is unsuccessful. Subject to appeal, I allow the amendments.
I award costs according to Schedule 8 against the opponent, Juno Pharmaceuticals Pty Ltd.
REASONS FOR DECISION
Background
Patent 2008340101 (the patent) was filed by Janssen Pharmaceutical NV (the patentee) on 17 December 2008 under the provisions of the Patent Cooperation Treaty as international application PCT/EP2008/067738 and claiming an earliest priority date of 19 December 2007. The patent was granted on 3 December 2015.
On 22 February 2023 the patentee sought leave to amend the specification, which amendments were subsequently superseded by further amendments filed on 17 May 2023. Leave to amend was granted and the amendments were advertised for opposition purposes on 15 June 2023.
Juno Pharmaceuticals Pty Ltd (the opponent) filed a notice of opposition to the allowance of the amendments on 15 August 2023 and a statement of grounds and particulars on 15 September 2023. The statement of grounds and particulars identifies as grounds of opposition to the amendments failure to comply with ss 102(3), 102(2)(a), 102(2)(b) and 102(1). At the hearing grounds of ss 102(2)(a), 102(2)(b) and 102(1) were pressed.
Evidence in support consists of a declaration by Professor Nicholas Keks dated 10 January 2024 (Keks) together with annexures NK-1 to NK-10 and a declaration by George Moksdi dated 10 January 2024 (Moksdi). Professor Keks was, as at the priority date, a clinical psychiatrist diagnosing and treating patients for schizophrenia or schizoaffective disorders.[1] He was also involved in clinical research projects and lectured to psychiatry students.[2] Mr Moksdi gives evidence as a patent and literature searcher of the publication date of various documents[3] but his evidence is not relied on by the opponent. Evidence in answer consists of a declaration by Professor Bruce Sugriv Singh dated 4 April 2024 (Singh) together with exhibits BSS-1 to BSS-5. Professor Singh has many years of experience as a medical practitioner specialising in psychiatry.[4] No evidence in reply was filed. I am satisfied that both Professor Keks and Professor Singh have backgrounds that enable them to…
Keep reading for free
Create a free CaseChat account to read Juno Pharmaceuticals Pty Ltd v Janssen Pharmaceutica NV and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2024] APO 48
- Decision Date
CaseChat Overview and Summary
The central legal issue before the court was whether the proposed amendments to the patent specification were allowable under section 102 of the Patents Act. Specifically, the court had to determine if the amendments met the criteria set out in section 102(2)(a) and (b), which relate to the content that 'arises' from the original application as filed. The court also needed to decide whether the amendments were allowable under section 104, which pertains to the opposition process and the grounds upon which an opponent may challenge the patent.
The court found that the amendments proposed by Janssen were allowable under the relevant sections of the Act. It held that the content in question did arise from the original application and met the criteria of section 102(2)(a) and (b). Furthermore, the court ruled that the opposition to the amendments was not valid under section 104, as the grounds for opposition did not meet the statutory requirements. Consequently, the court allowed the amendments and ordered Juno Pharmaceuticals to pay the costs of the proceedings.
The final orders of the court included the allowance of the patent amendments and the awarding of costs to Janssen Pharmaceutica NV against Juno Pharmaceuticals Pty Ltd. This decision underscored the importance of meeting the statutory criteria for patent amendments and the consequences of an unsuccessful opposition under the Patents Act.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.